Day-to-day hedonic and calming effects of opioids, opioid craving, and opioid misuse among patients with chronic pain prescribed long-term opioid therapy.
Journal
Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
25
06
2020
accepted:
16
12
2020
pubmed:
18
3
2021
medline:
4
8
2021
entrez:
17
3
2021
Statut:
ppublish
Résumé
Concerns have been raised regarding the misuse of opioids among patients with chronic pain. Although a number of factors may contribute to opioid misuse, research has yet to examine if the hedonic and calming effects that can potentially accompany the use of opioids contribute to opioid misuse. The first objective of this study was to examine the degree to which the hedonic and calming effects of opioids contribute to opioid misuse in patients with chronic pain. We also examined whether the hedonic and calming effects of opioids contribute to patients' daily levels of opioid craving, and whether these associations were moderated by patients' daily levels of pain intensity, catastrophizing, negative affect, or positive affect. In this longitudinal diary study, patients (n = 103) prescribed opioid therapy completed daily diaries for 14 consecutive days. Diaries assessed a host of pain, psychological, and opioid-related variables. The hedonic and calming effects of opioids were not significantly associated with any type of opioid misuse behavior. However, greater hedonic and calming effects were associated with heightened reports of opioid craving (both P's < 0.005). Analyses revealed that these associations were moderated by patients' daily levels of pain intensity, catastrophizing, and negative affect (all P's < 0.001). Results from this study provide valuable new insights into our understanding of factors that may contribute to opioid craving among patients with chronic pain who are prescribed long-term opioid therapy. The implications of our findings for the management of patients with chronic pain are discussed.
Identifiants
pubmed: 33729213
doi: 10.1097/j.pain.0000000000002220
pii: 00006396-202108000-00006
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2214-2224Subventions
Organisme : CIHR
Pays : Canada
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 International Association for the Study of Pain.
Références
Affleck G, Tennen H, Keefe FJ, Lefebvre JC, Kashikar-Zuck S, Wright K, Starr K, Caldwell DS. Everyday life with osteoarthritis or rheumatoid arthritis: independent effects of disease and gender on daily pain, mood, and coping. PAIN 1999;83:601–9.
Ballantyne JC. Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions. Anesth Analg 2017;125:1769–78.
Ballantyne JC, Sullivan MD. Discovery of endogenous opioid systems: what it has meant for the clinician's understanding of pain and its treatment. PAIN 2017;158:2290–300.
Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: a diathesis-stress framework. Psychol Bull 1996;119:95.
Becker WC, Fraenkel L, Edelman EJ, Holt SR, Glover J, Kerns RD, Fiellin DA. Instruments to assess patient-reported safety, efficacy, or misuse of current opioid therapy for chronic pain: a systematic review. PAIN 2013;154:905–16.
Becker WC, Merlin JS, Manhapra A, Edens EL. Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic. Addict Sci Clin Pract 2016;11:3.
Borsook D, Linnman C, Faria V, Strassman AM, Becerra L, Elman I. Reward deficiency and anti-reward in pain chronification. Neurosci Biobehav Rev 2016;68:282–97.
Broderick JE, Schwartz JE, Schneider S, Stone AA. Can End-of-day reports replace momentary assessment of pain and fatigue? J Pain 2009;10:274–81.
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, Mulla SM, Lopes LC, Vogel N, Chen E, Kirmayr K, De Oliveira K, Olivieri L, Kaushal A, Chaparro LE, Oyberman I, Agarwal A, Couban R, Tsoi L, Lam T, Vandvik PO, Hsu S, Bala MM, Schandelmaier S, Scheidecker A, Ebrahim S, Ashoorion V, Rehman Y, Hong PJ, Ross S, Johnston BC, Kunz R, Sun X, Buckley N, Sessler DI, Guyatt GH. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA 2018;320:2448–60.
Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain 2010;26:770–6.
Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN. Development and validation of the current opioid misuse measure. PAIN 2007;130:144–56.
Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain 2008;9:360–72.
Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007;32:912–23.
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162:276–86.
Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008;96:1–15.
Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. PAIN 2012;153:2315–24.
Compton PA, Wu SM, Schieffer B, Pham Q, Naliboff BD. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage 2008;36:383–95.
Darnall BD, Sturgeon JA, Cook KF, Taub CJ, Roy A, Burns JW, Sullivan M, Mackey SC. Development and validation of a daily pain catastrophizing scale. J Pain 2017;18:1139–49.
Davis MC, Okun MA, Kruszewski D, Zautra AJ, Tennen H. Sex differences in the relations of positive and negative daily events and fatigue in adults with rheumatoid arthritis. J Pain 2010;11:1338–47.
DeLongis A, Holtzman S. Coping in context: the role of stress, social support, and personality in coping. J Personal 2005;73:1633–56.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. PAIN 2005;113:9–19.
Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 2011;7:216–24.
Elman I, Borsook D. Common brain mechanisms of chronic pain and addiction. Neuron 2016;89:11–36.
Enders CK, Tofighi D. Centering predictor variables in cross-sectional multilevel models: a new look at an old issue. Psychol Methods 2007;12:121–38.
Fields HL, Margolis EB. Understanding opioid reward. Trends Neurosci 2015;38:217–25.
Finan PH, Quartana PJ, Smith MT. Positive and negative affect dimensions in chronic knee osteoarthritis: effects on clinical and laboratory pain. Psychosom Med 2013;75:463–70.
Garland EL, Atchley RM, Hanley AW, Zubieta JK, Froeliger B. Mindfulness-Oriented Recovery Enhancement remediates hedonic dysregulation in opioid users: neural and affective evidence of target engagement. Sci Adv 2019;5:eaax1569.
Garland EL, Bryan CJ, Finan PH, Thomas EA, Priddy SE, Riquino MR, Howard MO. Pain, hedonic regulation, and opioid misuse: modulation of momentary experience by Mindfulness-Oriented Recovery Enhancement in opioid-treated chronic pain patients. Drug Alcohol Depend 2017;173(suppl 1):S65–s72.
Garland EL, Bryan CJ, Nakamura Y, Froeliger B, Howard MO. Deficits in autonomic indices of emotion regulation and reward processing associated with prescription opioid use and misuse. Psychopharmacology (Berl) 2017;234:621–9.
Garland EL, Froeliger B, Howard MO. Effects of Mindfulness-Oriented Recovery Enhancement on reward responsiveness and opioid cue-reactivity. Psychopharmacology (Berl) 2014;231:3229–38.
Garland EL, Froeliger B, Howard MO. Neurophysiological evidence for remediation of reward processing deficits in chronic pain and opioid misuse following treatment with Mindfulness-Oriented Recovery Enhancement: exploratory ERP findings from a pilot RCT. J Behav Med 2015;38:327–36.
Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev 2013;37:2597–607.
Garland EL, Hanley AW, Kline A, Cooperman NA. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: ecological momentary assessments from a stage 1 randomized controlled trial. Drug Alcohol Depend 2019;203:61–5.
Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol 2014;82:448–59.
Garland EL, Trøstheim M, Eikemo M, Ernst G, Leknes S. Anhedonia in chronic pain and prescription opioid misuse. Psychol Med 2020;50:1977–88.
Gilam G, Sturgeon JA, You DS, Wasan AD, Darnall BD, Mackey SC. Negative Affect-Related Factors Have the Strongest Association with Prescription Opioid Misuse in a Cross-Sectional Cohort of Patients with Chronic Pain. Pain Med 2020;21:e127–e138.
Hayes AF. A primer on multilevel modeling. Hum Commun Res 2007;32:385–410.
Heck RH, Thomas SL, Tabata LN. Multilevel and Longitudinal Modeling with IBM SPSS. New York, NY: Taylor & Francis, 2014.
Holtzman S, Delongis A. One day at a time: the impact of daily satisfaction with spouse responses on pain, negative affect and catastrophizing among individuals with rheumatoid arthritis. PAIN 2007;131:202–13.
Jamison RN, Martel MO, Edwards RR, Qian J, Sheehan KA, Ross EL. Validation of a brief Opioid Compliance Checklist for patients with chronic pain. J Pain 2014;15:1092–101.
Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning? J Pain 2006;7:644–53.
Jones JD, Sullivan MA, Manubay J, Vosburg SK, Comer SD. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology 2011;36:411–22.
Juurlink DN. Rethinking "doing well" on chronic opioid therapy. CMAJ 2017;189:E1222-e1223.
Keefe FJ, Affleck G, Lefebvre JC, Starr K, Caldwell DS, Tennen H. Pain coping strategies and coping efficacy in rheumatoid arthritis: a daily process analysis. PAIN 1997;69:35–42.
Kerns RD, Sellinger J, Goodin BR. Psychological treatment of chronic pain. Annu Rev Clin Psychol 2011;7:411–34.
Kirsh KL, Jass C, Bennett DS, Hagen JE, Passik SD. Initial development of a survey tool to detect issues of chemical coping in chronic pain patients. Palliat Support Care 2007;5:219–26.
Kratz AL, Davis MC, Zautra AJ. Pain acceptance moderates the relation between pain and negative affect in female osteoarthritis and fibromyalgia patients. Ann Behav Med 2007;33:291–301.
Larsen RJ, Ketelaar T. Personality and susceptibility to positive and negative emotional states. J Personal Soc Psychol 1991;61:132–40.
Leknes S, Berna C, Lee MC, Snyder GD, Biele G, Tracey I. The importance of context: when relative relief renders pain pleasant. PAIN 2013;154:402–10.
Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nat Rev Neurosci 2008;9:314–20.
MacLean RR, Spinola S, Manhapra A, Sofuoglu M. Systematic review of pain severity and opioid craving in chronic pain and opioid use disorder. Pain Med 2020;21:e146-63.
Manhapra A, Becker WC. Pain and addiction: an integrative therapeutic approach. Med Clin North Am 2018;102:745–63.
Martel MO, Dolman AJ, Edwards RR, Jamison RN, Wasan AD. The association between negative affect and prescription opioid misuse in patients with chronic pain: the mediating role of opioid craving. J Pain 2014;15:90–100.
Martel MO, Finan PH, McHugh RK, Issa M, Edwards RR, Jamison RN, Wasan AD. Day-to-day pain symptoms are only weakly associated with opioid craving among patients with chronic pain prescribed opioid therapy. Drug Alcohol Depend 2016;162:130–6.
Martel MO, Edwards RR, Jamison RN. The relative contribution of pain and psychological factors to opioid misuse: A 6-month observational study. Am Psychol 2020;75:772–83.
McHugh RK, Fitzmaurice GM, Carroll KM, Griffin ML, Hill KP, Wasan AD, Weiss RD. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend 2014;145:121–6.
McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am 2010;33:511–25.
Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143–7.
Nezlek J. Multilevel random coefficient analyses of event and interval contingent data in social and personality psychology research. Psychol Bull 2001;27:771–85.
Ong AD, Bergeman CS, Bisconti TL, Wallace KA. Psychological resilience, positive emotions, and successful adaptation to stress in later life. J Personal Soc Psychol 2006;91:730–49.
Passik SD, Kirsh KL. Addictions in pain clinics and pain treatment. Ann N Y Acad Sci 2011;1216:138–43.
Passik SD, Squire P. Current risk assessment and management paradigms: snapshots in the life of the pain specialist. Pain Med 2009;10(suppl 2):S101–114.
Peugh JL. A practical guide to multilevel modeling. J Sch Psychol 2010;48:85–112.
Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother 2009;9:745–58.
Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract 2008;4:4–25.
Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess 2009;21:486–97.
Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl) 2006;184:608–18.
Shiffman S, Kirchner TR. Cigarette-by-cigarette satisfaction during ad libitum smoking. J Abnorm Psychol 2009;118:348–59.
Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. Oxford, United Kingdom; New York, NY: Oxford University Press, 2003.
Skinner HA. The drug abuse screening test. Addict Behav 1982;7:363–71.
Smith HS. Conventional practice for medical conditions for chronic opioid therapy. Pain Physician 2012;15:Es1-7.
Snijders T, Bosker R. Multilevel analysis: an introduction to basic and advanced multilevel modeling. London, United Kingdom: Sage, 1999.
Stone AA, Broderick JE, Schneider S, Schwartz JE. Expanding options for developing outcome measures from momentary assessment data. Psychosom Med 2012;74:387–97.
Sullivan M. Clarifying opioid misuse and abuse. PAIN 2013;154:2239–40.
Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32.
Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 2001;17:52–64.
Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 2004;5:133–7.
Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl) 2010;210:471–80.
Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of psychosocial and functional impact of chronic pain. J Pain 2016;17(9 suppl):T21–49.
Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. PAIN 2015;156:569–76.
Wasan AD, Ross EL, Michna E, Chibnik L, Greenfield SF, Weiss RD, Jamison RN. Craving of prescription opioids in patients with chronic pain: a longitudinal outcomes trial. J Pain 2012;13:146–54.
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Personal Soc Psychol 1988;54:1063.
West BT, Welch KB, Galecki AT. Linear Mixed Models: A practical guide using statistical software. London, United Kingdom: Chapman & Hall, 2007.
Wilsey BL, Fishman S, Li CS, Storment J, Albanese A. Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial. Pharmacol Biochem Behav 2009;94:98–107.
Zacny JP. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003;165:146–56.
Zacny JP. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend 2005;80:273–8.
Zacny JP. A possible link between sensation-seeking status and positive subjective effects of oxycodone in healthy volunteers. Pharmacol Biochem Behav 2010;95:113–20.
Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003;170:242–54.
Zautra AJ, Davis MC, Smith BW. Emotions, personality, and health: introduction to the special issue. J Personal 2004;72:1097–104.